-
Product Insights
NewHyaluronic Acid Fillers Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Hyaluronic Acid Fillers Pipeline Market Report Overview Hyaluronic Acid (HA) is a glycosaminoglycan disaccharide, which exists naturally in the body. Approximately 50% of the total HA is found in the skin. Injections of HA are used for reducing wrinkles in the face and for soft tissue augmentation. The hyaluronic acid fillers pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Luveltamab Tazevibulin in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Luveltamab Tazevibulin in Peritoneal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Luveltamab Tazevibulin in Peritoneal Cancer Drug Details: STRO-002 is under development...
-
Product Insights
Human Immunodeficiency Virus (HIV) Tests Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
HIV Tests Pipeline Market Report Overview Human Immunodeficiency Virus (HIV) tests refer to the antigens, antibodies, and nucleic acid reagent tests performed for the detection of HIV type I. The HIV Tests pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PL-001 in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PL-001 in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PL-001 in Primary Mediastinal B-Cell Lymphoma Drug Details: PL-001 is...
-
Product Insights
Chronic Urticaria Or Hives – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Urticaria Or Hives - Drugs In Development, 2023’, provides an overview of the Chronic Urticaria Or Hives pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PL-001 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PL-001 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PL-001 in Follicular Lymphoma Drug Details: PL-001 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PL-001 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PL-001 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PL-001 in Diffuse Large B-Cell Lymphoma Drug Details: PL-001 is...
-
Product Insights
Primary Mediastinal B-Cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Mediastinal B-Cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Primary Mediastinal B-Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Mediastinal B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Burkitt Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Burkitt Lymphoma - Drugs In Development, 2023’, provides an overview of the Burkitt Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Burkitt Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Liver Transplant Rejection – Drugs In Development, 2023
Global Markets Direct’s, ‘Liver Transplant Rejection - Drugs In Development, 2023’, provides an overview of the Liver Transplant Rejection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Liver Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...